Skip to Content
Merck
CN
All Photos(1)

Documents

59356-U

Supelco

Discovery® Cyano (5 µm) HPLC Columns

L × I.D. 15 cm × 4.6 mm, HPLC Column

Synonym(s):

Cyano Bonded Phase Column

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52

product name

Discovery® Cyano HPLC Column, 5 μm particle size, L × I.D. 15 cm × 4.6 mm

material

stainless steel column

Quality Level

100

Agency

suitable for USP L10

product line

Discovery®

feature

endcapped

manufacturer/tradename

Discovery®

packaging

1 ea of

extent of labeling

4.5% Carbon loading

parameter

≤70 °C temp. range
400 bar pressure (5801 psi)

technique(s)

HPLC: suitable
LC/MS: suitable

L × I.D.

15 cm × 4.6 mm

surface area

200 m2/g

surface coverage

3.5 μmol/m2

impurities

<10 ppm metals

matrix

silica gel, high purity, spherical base material
fully porous particle

matrix active group

cyano phase

particle size

5 μm

pore size

180 Å

operating pH range

2-8

application(s)

food and beverages

separation technique

hydrophilic interaction (HILIC)
normal phase
reversed phase

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Discovery® Cyano HPLC column is used for the retention and separation of strongly basic analytes including quaternary ammonium salts, with excellent peak shapes.

Features and Benefits

  • Low hydrophobicity for rapid elution of hydrophobic analytes
  • Excellent peak shape and retention of strongly basic analytes
  • Retention of polar analytes
  • Unique selectivity
  • Significantly less retention than C18 (typically requires lower % organic mobile phase)
  • Stable, low-bleed LC-MS separations
  • Compatible with highly aqueous organic phases

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
292156-04
292156-03
292156-02
292156-01
292155-06

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

E F Nemeth et al.
The Journal of pharmacology and experimental therapeutics, 299(1), 323-331 (2001-09-19)
Despite the discovery of many ions and molecules that activate the Ca2+ receptor, there are no known ligands that block this receptor. Reported here are the pharmacodynamic properties of a small molecule, NPS 2143, which acts as an antagonist at
Aaron D Milstein et al.
Trends in pharmacological sciences, 29(7), 333-339 (2008-06-03)
Presynaptic glutamate release elicits brief waves of membrane depolarization in neurons by activating AMPA receptors. Depending on its precise size and shape, current through AMPA receptors gates downstream processes like NMDA receptor activation and action potential generation. Over a decade
Graciela B Arhancet et al.
Journal of medicinal chemistry, 53(16), 5970-5978 (2010-08-03)
A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships
Aleem Gangjee et al.
Journal of medicinal chemistry, 53(22), 8116-8128 (2010-10-27)
Two classes of molecules were designed and synthesized based on a 6-CH(3) cyclopenta[d]pyrimidine scaffold and a pyrrolo[2,3-d]pyrimidine scaffold. The pyrrolo[2,3-d]pyrimidines were synthesized by reacting ethyl 2-cyano-4,4-diethoxybutanoate and acetamidine, which in turn was chlorinated and reacted with the appropriate anilines to
Srdan Verstovsek et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 14(3), 788-796 (2008-02-05)
The discovery of an activating somatic mutation in codon 617 of the gene encoding the Janus kinase (JAK)-2 (JAK2 V617F) in patients with myeloproliferative disorders has opened new avenues for the development of targeted therapies for these malignancies. However, no
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service